Telix – pharmaceutical daily

May 31, 2024 Off

Telix Announces Positive rPFS Data from ProstACT SELECT Trial of TLX591 rADC Therapy Candidate in Prostate Cancer

TLX591 is an investigational anti-PSMA1 radio-antibody-drug conjugate (rADC) therapy being developed for the treatment of mCRPC, differentiated by a short…

February 8, 2022 Off

Japanese Prostate Cancer Imaging Trial Meets Study Objectives

By GlobeNewswire

MELBOURNE, Australia and KYOTO, Japan, Feb. 08, 2022 (GLOBE NEWSWIRE) — Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) in…

October 24, 2017 Off

Telix, ANMI in JV to sell imaging prostate cancer technology

By Dino Mustafić

Telix Pharmaceuticals Limited focused on on targeted radiopharmaceuticals or molecularly-targeted radiation (MTR), has partnered up with Advanced Nuclear Medicine Ingredients SA (ANMI).…